Isoimperatorin Inhibits Angiogenesis by Suppressing VEGFR2 Signaling Pathway
ConclusionsOur study showed that isoimperatorin suppressed angiogenesis by targeting the VEGFR2 signaling pathway and could be a potential therapeutic agent for targeting angiogenesis. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 16, 2024 Category: Cardiology Source Type: research
A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids
ConclusionImportantly, IPE has been endorsed by 20 international medical societies as a statin add-on treatment in patients with dyslipidemia and high CV risk. Robust medical evidence supports IPE as a pillar in the management of dyslipidemia. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 16, 2024 Category: Cardiology Source Type: research
Isoimperatorin Inhibits Angiogenesis by Suppressing VEGFR2 Signaling Pathway
ConclusionsOur study showed that isoimperatorin suppressed angiogenesis by targeting the VEGFR2 signaling pathway and could be a potential therapeutic agent for targeting angiogenesis. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 16, 2024 Category: Cardiology Source Type: research
A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids
ConclusionImportantly, IPE has been endorsed by 20 international medical societies as a statin add-on treatment in patients with dyslipidemia and high CV risk. Robust medical evidence supports IPE as a pillar in the management of dyslipidemia. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 16, 2024 Category: Cardiology Source Type: research
Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis
ConclusionsAmong guideline-recommended antidysrhythmic drugs, the combination of digoxin IV and amiodarone IV is definitely among the least safe for cardioversion of recent onset AF; flecainide, vernakalant, ibutilide, propafenone, and amiodarone IV are definitely among the most effective for cardioversion within 4 h; flecainide is definitely among the most effective for cardioversion within 24 h. Further, randomized controlled trials with predetermined and strictly defined, hemodynamic adverse event outcomes are recommended. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 7, 2024 Category: Cardiology Source Type: research
Acute Kidney Injury in Different Anticoagulation Strategies: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data
ConclusionParticular attention should be directed toward monitoring renal function in individuals receiving anticoagulants, including warfarin and direct oral anticoagulants, as well as other anticoagulant agents. This diligence is particularly imperative within the first month after anticoagulant administration for individuals with a tendency for AKI. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 6, 2024 Category: Cardiology Source Type: research
The Case Continues to Build: More Data that Intracoronary Thrombolysis Is Safe and Effective in STEMI
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 6, 2024 Category: Cardiology Source Type: research
Dapagliflozin for Atrial Fibrillation
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 6, 2024 Category: Cardiology Source Type: research
Acute Kidney Injury in Different Anticoagulation Strategies: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data
ConclusionParticular attention should be directed toward monitoring renal function in individuals receiving anticoagulants, including warfarin and direct oral anticoagulants, as well as other anticoagulant agents. This diligence is particularly imperative within the first month after anticoagulant administration for individuals with a tendency for AKI. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 6, 2024 Category: Cardiology Source Type: research
The Case Continues to Build: More Data that Intracoronary Thrombolysis Is Safe and Effective in STEMI
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 6, 2024 Category: Cardiology Source Type: research
Dapagliflozin for Atrial Fibrillation
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 6, 2024 Category: Cardiology Source Type: research
The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding
AbstractBackgroundSodium glucose linked transporter 2 (SGLT2) inhibition not only reduces morbidity and mortality in patients with diagnosed heart failure but also prevents the development of heart failure hospitalization in those at risk. While studies to date have focused on the role of SGLT2 inhibition in left ventricular failure, whether this drug class is efficacious in the treatment and prevention of right heart failure has not been explored.HypothesisWe hypothesized that SGLT2 inhibition would reduce the structural, functional, and molecular responses to pressure overload of the right ventricle.MethodsThirteen-week-...
Source: Cardiovascular Drugs and Therapy - February 1, 2024 Category: Cardiology Source Type: research
IL-33 in Atherosclerosis: An Insufficiently Explored and Controversial Research Area
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 31, 2024 Category: Cardiology Source Type: research
